Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: methylnaltrexone Clear all
Completed Phase 4 Interventional Results available

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

NCT00672139
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

NCT00401375
View directory record Official record
Conditions
Post-Operative Ileus (POI)
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 1 Interventional

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

NCT01015222
View directory record Official record
Conditions
Advanced Cancer
Interventions
Dasatinib, Bevacizumab, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 3 Interventional

Open-Label Treatment Extension of Protocol MNTX 301

NCT01367600
View directory record Official record
Conditions
Terminal Illness
Interventions
SC Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Recruiting Phase 4 Interventional

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

NCT06162377
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Methylnaltrexone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 3 Interventional

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

NCT00402038
View directory record Official record
Conditions
Advance Illness Patients With OIC
Interventions
SC Methylnaltrexone, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone

NCT01367587
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IV Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

NCT01186770
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

NCT01366378
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Not listed Phase 3 Interventional

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

NCT01050595
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone Bromide, Placebo-Normal Saline
Drug
Lead sponsor
St. John Health System, Michigan
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets

NCT01366352
View directory record Official record
Conditions
Normal Volunteers
Interventions
MNTX tablet (Formulation 1), MNTX tablet (Formulation 2)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

NCT01004393
View directory record Official record
Conditions
Neoplasms, Constipation, Opioid-Related Disorders
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

NCT01367561
View directory record Official record
Conditions
Healthy Males
Interventions
Naloxone, IV Methylnaltrexone (MNTX), Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

NCT00528970
View directory record Official record
Conditions
Ileus
Interventions
MOA-728, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
75
States / cities
Benton, Arkansas • Colton, California • Laguna Hills, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Results available

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

NCT03523520
View directory record Official record
Conditions
Constipation Drug Induced
Interventions
Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

NCT01367574
View directory record Official record
Conditions
Bowel Dysfunction
Interventions
SC MNTX
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Withdrawn Phase 3 Interventional

Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates

NCT01360372
View directory record Official record
Conditions
Tube Feeding
Interventions
Methylnaltrexone, Saline injection
Drug
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tolerance and Pharmacokinetics Study of MNTX Tablets

NCT01366339
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Oral methylnaltrexone, Oral placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Terminated Phase 4 Interventional Results available

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

NCT02977286
View directory record Official record
Conditions
Constipation
Interventions
Naloxegol Oral Tablet, Placebo Oral Tablet, Docusate Sodium 100 Mg oral capsule [Colace], Senna 217 Mg Oral Tablet, Polyethylene Glycols, Bisacodyl 10 mg Suppository, Magnesium Citrate Oral Liquid Product, Methylnaltrexone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus

NCT01367548
View directory record Official record
Conditions
Postoperative Ileus
Interventions
IV Methylnaltrexone (MNTX), Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 3 Interventional

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

NCT00387309
View directory record Official record
Conditions
Post Operative Bowel Dysfunction
Interventions
Methylnaltrexone (MOA-728)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
59
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Chula Vista, California + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

NCT04787848
View directory record Official record
Conditions
Chronic Widespread Pain
Interventions
Relistor Injectable Product
Drug
Lead sponsor
Florida International University
Other
Eligibility
19 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 5:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function

NCT01367522
View directory record Official record
Conditions
Liver Dysfunction
Interventions
SC Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 27, 2026, 5:16 PM EDT
Withdrawn Phase 4 Interventional

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

NCT00858754
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
methylnaltrexone, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Laguna Hills, California • Lancaster, California • Flat Rock, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 27, 2026, 5:16 PM EDT